2nd Quarter - Report

THE MCMANUS GROUP for GENENTECH

Firm
Client
Income
$60,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

FDA approval and enforcement issues. Issues relating to S.3187, Food and Drug Administration Safety and Innovation Act. Issues relating to antibiotic development incentives in HR 2182 and S 1734, "Generating Antibiotic Incentives Now Act of 2011" (GAIN Act). Skin cancer awareness.

Foreign entity interest: 100% ownership by F. Hoffman-La Roche Ltd., Grenzacherstrasse 124, CH-4070 Basel, SUI

LobbyistCovered position, as disclosed
JOHN MCMANUS —
NICK SHIPLEY Legislative Director, Rep. Jay Inslee

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 3187 (112th), H.R. 2182 (112th)

Medicare/Medicaid MMM

Medicare coverage and payment of Part B drugs and biologicals.

Foreign entity interest: 100% ownership by F. Hoffman-La Roche Ltd., Grenzacherstrasse 124, CH-4070 Basel, SUI

LobbyistCovered position, as disclosed
JOHN MCMANUS —
NICK SHIPLEY Legislative Director, Rep. Jay Inslee

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.